Clinical Trial on a Natural Compound to Improve Chronic Inflammation After SARS-CoV-2 Infection

Inclusion Criteria: * Subjects of both sexes. * Subjects over 18 and under 70 years of age who have had a SARS-CoV-2 infection diagnosed by PDIA. * Subjects with a history of SARS-CoV-2 infection who, three months after the onset of COVID-19, continue to experience symptoms lasting at least two months that cannot be explained by another cause. These symptoms may be newly developed after initial recovery from an acute COVID-19 episode or persist from the initial illness. * No history of sequelae from a severe acute illness. Exclusion Criteria: * Subjects with an underlying disease that explains the clinical manifestations. * Presence of chronic inflammatory diseases. * Subjects with acute infections. * Evidence of active thromboembolic disorder, defined as those receiving parenteral anticoagulant or thrombolytic treatment. * Excessive alcohol consumption. * Hypersensitivity or intolerance to any of the components of the study products. * Use of any nutraceutical or dietary supplement. * Severe or terminal illnesses. * Subjects with a body mass index (BMI) over 32. * Pregnant or lactating women.